Read more here:
Bespoke Extracts Announces $100K Investment From CEO and Addition of New Brand Ambassador, UFC Fighter Maryna Moroz

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT®) as a treatment consideration to further lower atherosclerotic cardiovascular disease (ASCVD) in the appropriate patient population.”1

See the original post here:
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

Read more from the original source:
MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase

Immutep’s Collaboration and Exclusive License with GSK Remains in Place Immutep’s Collaboration and Exclusive License with GSK Remains in Place

See the original post here:
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

Highlights

Original post:
Immutep Quarterly Activities Report

Amsterdam, The Netherlands, January 22, 2021 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that four abstracts related to its K-NK-cell therapy platform were accepted for presentation at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), which is being held virtually from February 8–12, 2021.

View post:
Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation...

Go here to see the original:
Nicox Analyst Coverage Initiated by Edison Investment Research

Original post:
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in...

Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event.

Read the original here:
PCI Biotech to present at RNA Therapeutics Virtual Conference

Continued here:
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema

DENVER, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF).

Visit link:
Mydecine Innovations Group Included in First-Ever Psychedelics ETF

Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition.

See the original post:
aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.

Read the original here:
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT...

Press Release

Read this article:
Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021

Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda

See the article here:
Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform

Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases

See the rest here:
Albireo Recognizes International Alagille Syndrome Awareness Day 2021

BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission. Upon filing of the Form 10-Q on December 31, 2020, the Company regained compliance with Nasdaq Listing Rule 5250(c)(1) and this matter is now closed.

Read the original here:
Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule

GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 510,000 common shares effective January 21, 2021 at a price of $0.50 per share to a newly appointed director of the company. The options expire five years from the date of the grant, are subject to vesting and are governed by the terms of the company’s stock option plan.

More:
Bioasis Announces Stock Option Grant

ROLLING MEADOWS, Ill., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Cambium Networks Corporation (“Cambium Networks”) (NASDAQ: CMBM), a leading provider of wireless networking infrastructure solutions, today announced that it plans to report financial results for the fourth quarter and full year 2020 ended December 31, 2020 on Thursday, February 18, 2021.

View post:
Cambium Networks Corporation Announces Fourth Quarter and Full Year 2020 Reporting Date

TORONTO, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included in the First Psychedelics Exchange Traded Fund, which is managed by Horizons ETF Management.

See more here:
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund